Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
Open Access
- 15 May 2005
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (10), 3846-3853
- https://doi.org/10.1158/1078-0432.ccr-04-1950
Abstract
Purpose: To determine the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle.Keywords
This publication has 33 references indexed in Scilit:
- CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancerSeminars in Oncology, 2003
- Studies with ZD1839 in preclinical modelsSeminars in Oncology, 2003
- Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancerSeminars in Oncology, 2002
- Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapyThe EMBO Journal, 2002
- Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family InhibitionJournal of Biological Chemistry, 2001
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine KinasesJournal of Medicinal Chemistry, 1997
- Tyrosine Kinase Inhibition: An Approach to Drug DevelopmentScience, 1995
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987